Clinical Investigator Training Course, 43496-43497 [2014-17589]
Download as PDF
<![CDATA[
43496
Federal Register / Vol. 79, No. 143 / Friday, July 25, 2014 / Notices
www.fda.gov/Drugs/
GuidanceCompliance
RegulatoryInformation/Guidances/
default.htm, https://www.fda.gov/
BiologicsBloodVaccines/
GuidanceComplianceRegulatory
Information/Guidances/default.htm, or
https://www.regulations.gov.
Dated: July 22, 2014.
Leslie Kux,
Assistant Commissioner for Policy.
[FR Doc. 2014–17588 Filed 7–24–14; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2014–N–0001]
Clinical Investigator Training Course
AGENCY:
Food and Drug Administration,
HHS.
emcdonald on DSK67QTVN1PROD with NOTICES
ACTION:
Notice.
The Food and Drug Administration’s
(FDA’s) Center for Drug Evaluation and
Research/Office of Medical Policy and
the Duke University Office of
Continuing Medical Education are
cosponsoring a 3-day training course for
clinical investigators on scientific,
ethical, and regulatory aspects of
clinical trials. This training course is
intended to provide clinical
investigators with expertise in the
design, conduct, and analysis of clinical
trials; improve the quality of clinical
trials; and enhance the safety of trial
participants. Senior FDA staff will
communicate directly with clinical
investigators on issues of greatest
importance for successful clinical
research.
Date and Time: The training course
will be held on November 4 and 5, 2014,
from 8 a.m. to 5 p.m., and on November
6, 2014, from 8 a.m. to 3:30 p.m.
Location: The course will be held at
the Holiday Inn College Park, 10000
Baltimore Ave., College Park, MD
20740.
Contact Person: Tomeka Arnett,
Office of Medical Policy, Center for
Drug Evaluation and Research, Food
and Drug Administration, 10903 New
Hampshire Ave., Bldg. 51, Rm. 6355,
Silver Spring, MD 20993, 301–796–
8486.
Registration: Register by October 17,
2014. The registration fee is $150 per
person. The fee includes course
materials and onsite lunch. Early
registration is recommended because
seating is limited. There will be no
onsite registration.
VerDate Mar<15>2010
18:34 Jul 24, 2014
Jkt 232001
Register online for the training course
at the registration Web site https://
continuingeducation.dcri.duke.edu/citc
or download a full-size copy of the
registration form from the registration
site and mail a check and completed
form to Duke Clinical Research Institute
(DCRI), Attention—Duke CME/CEE, 300
West Morgan St., Suite 800, Durham,
NC 27701. You will receive an email
that confirms your registration. (FDA
has verified the Web site address, but
FDA is not responsible for subsequent
changes to the Web site after this
document publishes in the Federal
Register.)
Attendees are responsible for their
own accommodations. A block of rooms
has been reserved under ‘‘FDA Clinical
Investigator Course’’ at the Holiday Inn
College Park at a reduced conference
rate. Reservations for these
accommodations can be made online
using the course registration Web site
mentioned previously. Click on
‘‘registration form.’’ You will see a
direct link to the hotel.
Registration materials, payment
procedures, accommodation
information, and a detailed description
of the course can be found at the
registration/information Web site
mentioned previously.
If you need special accommodations
due to a disability, please contact
Tomeka Arnett (see Contact Person) at
least 7 days in advance. Persons
attending the course are advised that
FDA is not responsible for providing
access to electrical outlets.
SUPPLEMENTARY INFORMATION:
I. Background
Clinical trial investigators play a
critical role in the development of
medical products. They bear the
responsibility for ensuring the safe and
ethical treatment of study subjects and
for acquiring adequate and reliable data
to support regulatory decisions. This
course is intended to assist clinical
investigators in understanding what
preclinical and clinical information is
needed to support the investigational
use of medical products, as well as the
scientific, regulatory, and ethical
considerations involved in the conduct
of clinical trials. The course will cover
a wide variety of key topics, including
material on novel safety concerns,
adverse event monitoring, compliance
with the legal and ethical obligations of
clinical research, and acceptable
scientific and analytic standards in the
design and conduct of clinical studies.
The faculty will include a diverse
representation of senior FDA staff,
enabling FDA to communicate directly
with clinical investigators on issues of
PO 00000
Frm 00109
Fmt 4703
Sfmt 4703
greatest importance for successful
clinical research.
II. Description of the Training Course
A. Purpose
The training course is designed to
provide clinical investigators with an
overview of the following information:
• The essential toxicological,
pharmacological, and manufacturing
data to support investigational use in
humans;
• fundamental issues in the design
and conduct of clinical trials;
• statistical and analytic
considerations in the interpretation of
trial data;
• appropriate safety evaluation
during studies; and
• the ethical considerations and
regulatory requirements for clinical
trials.
In addition, the course should
accomplish the following:
• Foster a cadre of clinical
investigators with knowledge,
experience, and commitment to
investigational medicine;
• promote communication between
clinical investigators and FDA;
• enhance investigators’
understanding of FDA’s role in
experimental medicine; and
• improve the quality of data while
enhancing subject protection in the
performance of clinical trials.
B. Proposed Agenda
The course will be conducted over 3
days and comprises approximately 26
lectures, each lasting between 30 and 45
minutes. The course will be presented
mainly by senior FDA staff, with guest
lecturers presenting selected topics.
The course will address FDA’s role in
clinical studies and regulatory
considerations for clinical trials and
will include a review of the material
generally appearing in an ‘‘investigator’s
brochure,’’ i.e., the preclinical
information (toxicology, animal studies,
and chemistry/manufacturing
information) that supports initial
clinical trials in humans. Presenters will
discuss the role of clinical
pharmacology in early clinical studies
and how this information is used in the
design of subsequent studies. The
course will also include discussions of
scientific, statistical, ethical, and
regulatory aspects of clinical studies. On
November 6, 2014, participants will
choose among three breakout sessions
that will explain how to put together an
application to FDA for drugs, biologics,
or devices.
E:\FR\FM\25JYN1.SGM
25JYN1
43497
Federal Register / Vol. 79, No. 143 / Friday, July 25, 2014 / Notices
C. Target Audience
The course is targeted toward health
care professionals responsible for, or
involved in, the conduct and/or design
of clinical trials.
Dated: July 22, 2014.
Leslie Kux,
Assistant Commissioner for Policy.
[FR Doc. 2014–17589 Filed 7–24–14; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Substance Abuse and Mental Health
Services Administration
Agency Information Collection
Activities: Submission for OMB
Review; Comment Request
Periodically, the Substance Abuse and
Mental Health Services Administration
(SAMHSA) will publish a summary of
information collection requests under
OMB review, in compliance with the
Paperwork Reduction Act (44 U.S.C.
Chapter 35). To request a copy of these
documents, call the SAMHSA Reports
Clearance Officer on (240) 276–1243.
Project: SAMHSA SOAR Web-Based
Data Form (OMB No. 0930–0329)—
Revision.
In 2009 the Substance Abuse and
Mental Health Services Administration
(SAMHSA) of the U.S. Department of
Health and Human Services created a
Technical Assistance Center to assist in
the implementation of the SSI/SSDI
Outreach Access and Recovery (SOAR)
effort in all states. SOAR’s primary
objective is to improve the allowance
rate for Social Security Administration
(SSA) disability benefits for people who
are homeless or at risk of homelessness,
and who have serious mental illnesses.
During the SOAR training, the
importance of keeping track of SSI/SSDI
applications through the process is
stressed. In response to requests from
states implementing SOAR, the
Technical Assistance Center under
SAMHSA’s direction developed a webbased data form that case managers can
use to track the progress of submitted
applications, including decisions
received from SSA either on initial
application or on appeal. This
password-protected web-based data
form is housed on the SOAR Web site
(https://soartrack.prainc.com). Use of
this form is completely voluntary.
In addition, data from the web-based
form can be compiled into reports on
decision results and the use of SOAR
core components, such as the SSA–1696
Appointment of Representative, which
allows SSA to communicate directly
with the case manager assisting with the
application. These reports will be
reviewed by agency directors, SOAR
state-level leads, and the national SOAR
Technical Assistance Center and SOAR
national evaluation team to quantify the
success of the effort overall and to
identify areas where additional
technical assistance is needed. The
changes to this form are an added
question about the reason for denial, if
received and an added ten optional
questions about Medicaid and Medicare
reimbursement amounts, back payments
and applicants’ work involvement and
earnings. These data provide important
tools in local and state sustainability
efforts of SOAR. If caseworkers do not
have this information, they can simply
leave the items blank.
The estimated response burden is as
follows:
Number of
respondents
Responses
per
respondent
Total
responses
Hours per
response
Total
hours
SOAR Data Form .................................................................
emcdonald on DSK67QTVN1PROD with NOTICES
Information source
700
3
2100
.25
525
Written comments and
recommendations concerning the
proposed information collection should
be sent by August 25, 2014 to the
SAMHSA Desk Officer at the Office of
Information and Regulatory Affairs,
Office of Management and Budget
(OMB). To ensure timely receipt of
comments, and to avoid potential delays
in OMB’s receipt and processing of mail
sent through the U.S. Postal Service,
commenters are encouraged to submit
their comments to OMB via email to:
OIRA_Submission@omb.eop.gov.
Although commenters are encouraged to
send their comments via email,
commenters may also fax their
comments to: 202–395–7285.
Commenters may also mail them to:
Office of Management and Budget,
Office of Information and Regulatory
Affairs, New Executive Office Building,
Room 10102, Washington, DC 20503.
Summer King,
Statistician.
[FR Doc. 2014–17521 Filed 7–24–14; 8:45 am]
BILLING CODE 4162–20–P
VerDate Mar<15>2010
18:34 Jul 24, 2014
Jkt 232001
DEPARTMENT OF HOUSING AND
URBAN DEVELOPMENT
[Docket No. FR–5753–N–03]
60-Day Notice of Proposed Information
Collection: Housing Opportunities for
Persons With AIDS (HOPWA) Program:
Annual Grantee Performance
Reporting Requirements and
Competitive/Renewal Grant Project
Budget Summary
Office of the Assistant
Secretary for Community Planning and
Development, HUD.
ACTION: Notice of proposed information
collection.
AGENCY:
HUD is seeking approval from
the Office of Management and Budget
(OMB) for the information collection
described below. In accordance with the
Paperwork Reduction Act, HUD is
requesting comment from all interested
parties on the proposed collection of
information. The purpose of this notice
is to allow for 60 days of public
comment.
DATES: Comments Due Date: September
23, 2014.
SUMMARY:
PO 00000
Frm 00110
Fmt 4703
Sfmt 4703
Interested persons are
invited to submit comments regarding
this proposal. Comments should refer to
the proposal by name and/or OMB
Control Number and should be sent to:
Colette Pollard, Reports Management
Officer, QDAM, Department of Housing
and Urban Development, 451 7th Street
SW., Washington, DC 20410; email
Colette Pollard at Colette.Pollard@
hud.gov or telephone 202–402–3400, for
a copy of the proposed forms or other
available information. Persons with
hearing or speech impairments may
access this number through TTY by
calling the toll-free Federal Relay
Service at (800) 877–8339.
FOR FURTHER INFORMATION CONTACT: Eric
Pfeifer, Management Analyst, CPD,
Office of HIV/AIDS Housing,
Department of Housing and Urban
Development, 451 7th Street SW., Room
7212, Washington, DC 20410–5000;
telephone 202–708–1934 (this is not a
toll-free number) or email at
eric.m.pfeifer@hud.gov. This is not a
toll-free number. Persons with hearing
or speech impairments may access this
number through TTY by calling the tollfree Federal Relay Service at (800) 877–
ADDRESSES:
E:\FR\FM\25JYN1.SGM
25JYN1
]]>Agencies
[Federal Register Volume 79, Number 143 (Friday, July 25, 2014)]
[Notices]
[Pages 43496-43497]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2014-17589]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2014-N-0001]
Clinical Investigator Training Course
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
The Food and Drug Administration's (FDA's) Center for Drug
Evaluation and Research/Office of Medical Policy and the Duke
University Office of Continuing Medical Education are cosponsoring a 3-
day training course for clinical investigators on scientific, ethical,
and regulatory aspects of clinical trials. This training course is
intended to provide clinical investigators with expertise in the
design, conduct, and analysis of clinical trials; improve the quality
of clinical trials; and enhance the safety of trial participants.
Senior FDA staff will communicate directly with clinical investigators
on issues of greatest importance for successful clinical research.
Date and Time: The training course will be held on November 4 and
5, 2014, from 8 a.m. to 5 p.m., and on November 6, 2014, from 8 a.m. to
3:30 p.m.
Location: The course will be held at the Holiday Inn College Park,
10000 Baltimore Ave., College Park, MD 20740.
Contact Person: Tomeka Arnett, Office of Medical Policy, Center for
Drug Evaluation and Research, Food and Drug Administration, 10903 New
Hampshire Ave., Bldg. 51, Rm. 6355, Silver Spring, MD 20993, 301-796-
8486.
Registration: Register by October 17, 2014. The registration fee is
$150 per person. The fee includes course materials and onsite lunch.
Early registration is recommended because seating is limited. There
will be no onsite registration.
Register online for the training course at the registration Web
site https://continuingeducation.dcri.duke.edu/citc or download a full-
size copy of the registration form from the registration site and mail
a check and completed form to Duke Clinical Research Institute (DCRI),
Attention--Duke CME/CEE, 300 West Morgan St., Suite 800, Durham, NC
27701. You will receive an email that confirms your registration. (FDA
has verified the Web site address, but FDA is not responsible for
subsequent changes to the Web site after this document publishes in the
Federal Register.)
Attendees are responsible for their own accommodations. A block of
rooms has been reserved under ``FDA Clinical Investigator Course'' at
the Holiday Inn College Park at a reduced conference rate. Reservations
for these accommodations can be made online using the course
registration Web site mentioned previously. Click on ``registration
form.'' You will see a direct link to the hotel.
Registration materials, payment procedures, accommodation
information, and a detailed description of the course can be found at
the registration/information Web site mentioned previously.
If you need special accommodations due to a disability, please
contact Tomeka Arnett (see Contact Person) at least 7 days in advance.
Persons attending the course are advised that FDA is not responsible
for providing access to electrical outlets.
SUPPLEMENTARY INFORMATION:
I. Background
Clinical trial investigators play a critical role in the
development of medical products. They bear the responsibility for
ensuring the safe and ethical treatment of study subjects and for
acquiring adequate and reliable data to support regulatory decisions.
This course is intended to assist clinical investigators in
understanding what preclinical and clinical information is needed to
support the investigational use of medical products, as well as the
scientific, regulatory, and ethical considerations involved in the
conduct of clinical trials. The course will cover a wide variety of key
topics, including material on novel safety concerns, adverse event
monitoring, compliance with the legal and ethical obligations of
clinical research, and acceptable scientific and analytic standards in
the design and conduct of clinical studies. The faculty will include a
diverse representation of senior FDA staff, enabling FDA to communicate
directly with clinical investigators on issues of greatest importance
for successful clinical research.
II. Description of the Training Course
A. Purpose
The training course is designed to provide clinical investigators
with an overview of the following information:
The essential toxicological, pharmacological, and
manufacturing data to support investigational use in humans;
fundamental issues in the design and conduct of clinical
trials;
statistical and analytic considerations in the
interpretation of trial data;
appropriate safety evaluation during studies; and
the ethical considerations and regulatory requirements for
clinical trials.
In addition, the course should accomplish the following:
Foster a cadre of clinical investigators with knowledge,
experience, and commitment to investigational medicine;
promote communication between clinical investigators and
FDA;
enhance investigators' understanding of FDA's role in
experimental medicine; and
improve the quality of data while enhancing subject
protection in the performance of clinical trials.
B. Proposed Agenda
The course will be conducted over 3 days and comprises
approximately 26 lectures, each lasting between 30 and 45 minutes. The
course will be presented mainly by senior FDA staff, with guest
lecturers presenting selected topics.
The course will address FDA's role in clinical studies and
regulatory considerations for clinical trials and will include a review
of the material generally appearing in an ``investigator's brochure,''
i.e., the preclinical information (toxicology, animal studies, and
chemistry/manufacturing information) that supports initial clinical
trials in humans. Presenters will discuss the role of clinical
pharmacology in early clinical studies and how this information is used
in the design of subsequent studies. The course will also include
discussions of scientific, statistical, ethical, and regulatory aspects
of clinical studies. On November 6, 2014, participants will choose
among three breakout sessions that will explain how to put together an
application to FDA for drugs, biologics, or devices.
[[Page 43497]]
C. Target Audience
The course is targeted toward health care professionals responsible
for, or involved in, the conduct and/or design of clinical trials.
Dated: July 22, 2014.
Leslie Kux,
Assistant Commissioner for Policy.
[FR Doc. 2014-17589 Filed 7-24-14; 8:45 am]
BILLING CODE 4164-01-P
